Zobrazeno 1 - 10
of 76
pro vyhledávání: '"Michelle L. Hastings"'
Autor:
Ria Thomas, Kyle J. Connolly, Oeystein R. Brekk, Anthony J. Hinrich, Michelle L. Hastings, Ole Isacson, Penelope J. Hallett
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-14 (2023)
Abstract Inflammatory processes and mechanisms are of central importance in neurodegenerative diseases. In the brain, α-synucleinopathies such as Parkinson’s disease (PD) and Lewy body dementia (LBD) show immune cytokine network activation and inc
Externí odkaz:
https://doaj.org/article/19fde4928a4f45e5b0fc284e1cba2d1f
Autor:
Joanna A. Korecka, Ria Thomas, Anthony J. Hinrich, Alyssa M. Moskites, Zach K. Macbain, Penelope J. Hallett, Ole Isacson, Michelle L. Hastings
Publikováno v:
Molecular Therapy: Nucleic Acids, Vol 21, Iss , Pp 623-635 (2020)
Parkinson’s disease (PD) is a progressive neurological disorder estimated to affect 7–10 million people worldwide. There is no treatment available that cures or slows the progression of PD. Elevated leucine-rich repeat kinase 2 (LRRK2) activity h
Externí odkaz:
https://doaj.org/article/c35d1d9940544cb3b606f79c91e2929b
Autor:
Joanna A. Korecka, Sebastien Talbot, Teresia M. Osborn, Sherida M. de Leeuw, Simon A. Levy, Eliza J. Ferrari, Alyssa Moskites, Elise Atkinson, Francine M. Jodelka, Anthony J. Hinrich, Michelle L. Hastings, Clifford J. Woolf, Penelope J. Hallett, Ole Isacson
Publikováno v:
Stem Cell Reports, Vol 12, Iss 1, Pp 29-41 (2019)
Summary: The Parkinson disease (PD) genetic LRRK2 gain-of-function mutations may relate to the ER pathological changes seen in PD patients at postmortem. Human induced pluripotent stem cell (iPSC)-derived neurons with the PD pathogenic LRRK2 G2019S m
Externí odkaz:
https://doaj.org/article/872a0bc4898b44ba96fb040e2470c7bb
Autor:
Ashley A Blackwell, Francine M Jodelka, Rami I. Lake, Michelle L. Hastings, Douglas G. Wallace
Publikováno v:
Neuroscience. 511:53-69
Alzheimer's disease (AD) is associated with hippocampal neuropathology and cognitive impairments, including wandering behavior or becoming lost in a familiar environment. Wandering behavior is severe and manifests early in life for people with specif
Publikováno v:
RNA. 29:393-395
“RNA therapeutics” refers to a disease treatment or drug that utilizes RNA as a component. In this context, RNA may be the direct target of a small-molecule drug or RNA itself may be the drug, designed to bind to a protein, or to mimic or target
Autor:
Anthony J Hinrich, Francine M Jodelka, Jennifer L Chang, Daniella Brutman, Angela M Bruno, Clark A Briggs, Bryan D James, Grace E Stutzmann, David A Bennett, Steven A Miller, Frank Rigo, Robert A Marr, Michelle L Hastings
Publikováno v:
EMBO Molecular Medicine, Vol 8, Iss 4, Pp 328-345 (2016)
Abstract Apolipoprotein E receptor 2 (ApoER2) is an apolipoprotein E receptor involved in long‐term potentiation, learning, and memory. Given its role in cognition and its association with the Alzheimer's disease (AD) risk gene, apoE, ApoER2 has be
Externí odkaz:
https://doaj.org/article/53d79b4ef2ba4429a49c1630f225c643
Autor:
Derek Timm, Jacob T Cain, Ryan D Geraets, Katherine A White, Seung Yon Koh, Tammy Kielian, David A Pearce, Michelle L Hastings, Jill M Weimer
Publikováno v:
PLoS ONE, Vol 13, Iss 8, p e0201470 (2018)
CLN3-Batten disease is a rare, autosomal recessive disorder involving seizures, visual, motor and cognitive decline, and premature death. The Cln3Δex7/8 mouse model recapitulates several phenotypic characteristics of the most common 1.02kb disease-a
Externí odkaz:
https://doaj.org/article/1d107ecde9b04446bdecf6b33b0ce7da
Autor:
Jessica L, Centa, Michelle L, Hastings
Publikováno v:
Methods in molecular biology (Clifton, N.J.). 2537
Targeting of pre-mRNA splicing has yielded a rich variety of strategies for altering gene expression as a treatment for disease. The search for therapeutics that can modulate splicing has been dominated by antisense oligonucleotides (ASOs) and small
Autor:
Michelle L. Hastings, Zach K. Macbain, Joanna A. Korecka, Ole Isacson, Anthony J. Hinrich, Ria Thomas, Penelope J. Hallett, Alyssa Moskites
Publikováno v:
Molecular Therapy: Nucleic Acids, Vol 21, Iss, Pp 623-635 (2020)
Molecular Therapy. Nucleic Acids
Molecular Therapy. Nucleic Acids
Parkinson’s disease (PD) is a progressive neurological disorder estimated to affect 7–10 million people worldwide. There is no treatment available that cures or slows the progression of PD. Elevated leucine-rich repeat kinase 2 (LRRK2) activity h
Autor:
Jessica L. Centa, Frank Rigo, Francine M. Jodelka, Anthony J. Hinrich, Joseph Ochaba, Dominik M. Duelli, Michaela Jackson, Tyler B. Johnson, Jill M. Weimer, Michelle L. Hastings
Publikováno v:
Nat Med
CLN3 Batten disease is an autosomal recessive, neurodegenerative, lysosomal storage disease caused by mutations in CLN3, which encodes a lysosomal membrane protein(1–3). There are no disease-modifying treatments for this disease that affects up to